ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,601 to 2,620 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Torsemide vs Furosemide: All-cause Mortality, as Measured by Follow-up Phone Call or NDI373 of 1,431

374 of 1,428

-0.1 points

-3.3 to 3.1

2,859NCT03296813

TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure

Torsemide vs Furosemide: All-cause Mortality or All-cause Hospitalization, as Measured by Follow-up Phone Call or NDI (for Death)677 of 1,431

704 of 1,428

-2.0 points

-5.6 to 1.7

2,859NCT03296813

TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure

Torsemide vs Furosemide: deaths from any cause373 of 1,431

374 of 1,428

-0.1 points

-3.3 to 3.1

2,859NCT03296813

TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure

Tofacitinib 10 mg vs Tofacitinib 5 mg or 10 mg: Number of Participants With Laboratory Abnormalities2,203 of 2,271

565 of 578

-0.7 points

-2.0 to 0.9

2,849NCT01163253

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Tofacitinib 10 mg vs Tofacitinib 5 mg or 10 mg: Number of Participants With Clinically Significant Change From Baseline in Physical Examination683 of 2,268

191 of 577

-3.0 points

-7.3 to 1.2

2,845NCT01163253

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Varenicline - With Antipsychotics as a Concomitant Drug vs Varenicline - Without Antipsychotics as a Concomitant Drug: Risk Factors for the Proportion of Responders - Antipsychotics as a Concomitant Drug.85 of 140

2,111 of 2,702

-17.4 points

-25.8 to -9.5

2,842NCT00772941

Drug Use Investigation Of Varenicline (Regulatory Post Marketing Commitment Plan)

Betamethasone vs Placebo: deaths from any cause2 of 1,429

0 of 1,402

0.1 points

-0.2 to 0.5

2,831NCT01222247

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Betamethasone vs Placebo: serious adverse events13 of 1,429

12 of 1,402

0.1 points

-0.7 to 0.8

2,831NCT01222247

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Intensive Blood-Pressure Lowering vs Guideline-Recommended Blood-Pressure Lowering: serious adverse events324 of 1,399

329 of 1,430

0.2 points

-3.0 to 3.3

2,829NCT00716079

The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial

Betamethasone vs Placebo: Number of Infants With Neonatal Sepsis9 of 1,427

11 of 1,400

-0.2 points

-0.8 to 0.5

2,827NCT01222247

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Betamethasone vs Placebo: Neonatal Feeding Difficulty211 of 1,427

223 of 1,400

-1.1 points

-3.8 to 1.5

2,827NCT01222247

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Betamethasone vs Placebo: Number of Neonates With Necrotizing Enterocolitic (NEC)0 of 1,427

1 of 1,400

-0.1 points

-0.4 to 0.2

2,827NCT01222247

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Betamethasone vs Placebo: Number of Neonates Needing Surfactant Administration26 of 1,427

43 of 1,400

-1.2 points

-2.4 to -0.1

2,827NCT01222247

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Betamethasone vs Placebo: Neonatal Morbidity Composite81 of 1,427

90 of 1,400

-0.8 points

-2.5 to 1.0

2,827NCT01222247

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Betamethasone vs Placebo: Birth Weight Less Than 10th Percentile255 of 1,427

220 of 1,400

2.2 points

-0.6 to 4.9

2,827NCT01222247

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Betamethasone vs Placebo: Number of Infants With Neonatal Apnea33 of 1,427

37 of 1,400

-0.3 points

-1.5 to 0.8

2,827NCT01222247

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Betamethasone vs Placebo: Number of Neonates With Hypothermia132 of 1,427

112 of 1,400

1.3 points

-0.8 to 3.3

2,827NCT01222247

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Betamethasone vs Placebo: Neonates With Pneumonia6 of 1,427

13 of 1,400

-0.5 points

-1.2 to 0.1

2,827NCT01222247

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Betamethasone vs Placebo: Number of Neonates With Intraventricular Hemorrhage2 of 1,427

0 of 1,400

0.1 points

-0.2 to 0.5

2,827NCT01222247

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Betamethasone vs Placebo: Number of Neonates With Pulmonary Air Leak5 of 1,427

6 of 1,400

-0.1 points

-0.6 to 0.4

2,827NCT01222247

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=131"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=131

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT03296813-a084e1c1",
        "title": "Torsemide vs Furosemide: All-cause Mortality, as Measured by Follow-up Phone Call or NDI",
        "summary": "373 of 1431 against 374 of 1428; risk difference -0.1 points, 95% interval -3.3 to 3.1; NCT03296813, TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure",
        "record": "/library/comparisons/NCT03296813-a084e1c1",
        "nct_id": "NCT03296813",
        "kind": "outcome",
        "participants": 2859,
        "risk_difference": {
          "value": -0.0012478786063692127,
          "lower": -0.033437946453449954,
          "upper": 0.030942685797791643
        },
        "group_1": "373 of 1,431",
        "group_2": "374 of 1,428",
        "difference": "-0.1 points",
        "interval": "-3.3 to 3.1",
        "trial_title": "TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure"
      },
      {
        "id": "NCT03296813-ac4dc5ca",
        "title": "Torsemide vs Furosemide: All-cause Mortality or All-cause Hospitalization, as Measured by Follow-up Phone Call or NDI (for Death)",
        "summary": "677 of 1431 against 704 of 1428; risk difference -2.0 points, 95% interval -5.6 to 1.7; NCT03296813, TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure",
        "record": "/library/comparisons/NCT03296813-ac4dc5ca",
        "nct_id": "NCT03296813",
        "kind": "outcome",
        "participants": 2859,
        "risk_difference": {
          "value": -0.01990146163287121,
          "lower": -0.05644226996069097,
          "upper": 0.016714488756369647
        },
        "group_1": "677 of 1,431",
        "group_2": "704 of 1,428",
        "difference": "-2.0 points",
        "interval": "-5.6 to 1.7",
        "trial_title": "TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=132",
  "request_id": "1DC6_ZOlqoOuTNA8"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?